Table 2.
Cumulative vaginal sex during follow-up, by week and dose*
| Day | Cumulative vaginal sexual intercourse since treatment |
|---|---|
| Total cohort | |
| 7 | 17/86 (19.8%) |
| 14 | 35/89 (39.3%) |
| 21 | 44/89 (49.4%) |
| 28 | 54/89 (60.7%) |
| Single dose | |
| 7 | 11/52 (21.2%) |
| 14 | 25/54 (46.3%) |
| 21 | 34/54 (63.0%) |
| 28 | 40/54 (74.1%) |
| 7-day dose | |
| 7 | 6/34 (17.6%) |
| 14 | 10/35 (28.6%) |
| 21 | 10/35 (28.6%) |
| 28 | 14/35 (40.0%) |
Women self-reported either condom use or that both she and her partner(s) had been treated before sexual intercourse.